This is the authors' abstract. We don't add key points for this paper.
The NLRP3 inflammasome has emerged as an important regulator of inflammatory signaling in cardiovascular disease. However, its contribution to β-adrenergic-induced cardiomyocyte hypertrophy remains poorly understood. Here, we investigated the role of NLRP3 in isoproterenol (ISO)-induced hypertrophy using differentiated human AC16 cardiomyocytes. We first demonstrate that differentiated AC16 cells constitute a robust human-derived model for studying cardiomyocyte hypertrophy, exhibiting reduced proliferative activity and a differentiated phenotype suitable for hypertrophic and signaling studies. β-Adrenergic stimulation with ISO induced a hypertrophic phenotype characterized by increased cell surface area and upregulation of canonical hypertrophic markers, including NPPA, MYH7, BMP2, TNNI3, and GATA4. ISO also promoted activation of the NLRP3 inflammasome, whereas pharmacological inhibition with the selective NLRP3 inhibitor MCC950 markedly attenuated cardiomyocyte hypertrophy and suppressed the induction of hypertrophic markers. To define the signaling mechanisms underlying these effects, we performed a phospho-kinase array, which revealed that NLRP3 inhibition broadly reshaped the ISO-induced phosphoproteomic profile, significantly modulating signaling pathways involving p53, PLC-γ1, Src, ERK1/2, JNK, and GSK-3β. Collectively, our study identifies NLRP3 as a critical regulator of β-adrenergic signaling that couple inflammatory and hypertrophic responses in human cardiomyocytes.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Cerri et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: